Additional Proxy Soliciting Materials (definitive) (defa14a)
March 23 2021 - 4:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
SCHEDULE 14A
INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
Filed by the
Registrant ☒ Filed by a Party other than the
Registrant ☐
Check the appropriate box:
|
|
|
|
|
☐
|
|
Preliminary Proxy Statement
|
|
|
|
|
☐
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
|
|
☐
|
|
Definitive Proxy Statement
|
|
|
|
|
☒
|
|
Definitive Additional Materials
|
|
|
|
|
☐
|
|
Soliciting Material under Rule 14a-12
|
MEDNAX, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if
Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
|
|
|
☒
|
|
No Fee Required.
|
|
|
|
|
☐
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
(5)
|
|
Total fee paid:
|
|
|
|
|
☐
|
|
Fee paid previously with preliminary materials:
|
|
|
|
|
☐
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
|
(3)
|
|
Filing Party:
|
|
|
|
(4)
|
|
Date Filed:
|
MEDNAX, INC. 1301 CONCORD TERRACE SUNRISE, FL 33323-2825 Your Vote Counts! Mednax, Inc. 2021 Annual Meeting Vote by May 11, 2021
11:59 PM ET for shares directly held. For shares held in a Plan (as defined in the Proxy Statement), vote by May 7, 2021 11:59 PM ET. D43203-P51249-Z79304 You invested in Mednax, Inc. and it’s time to vote! You have the right to vote on
proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on May 12, 2021. Get informed before you vote View the Notice and Proxy Statement
and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 28, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may
(1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If
sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone
users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 12, 2021 10:30 AM ET Virtually at: www.virtualshareholdermeeting.com/MD2021 *Please check the meeting materials for any special
requirements for meeting attendance. V1 V1
Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder
meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors Nominees: 01) Karey D. Barker 04) Manuel Kadre 07) Mark S. Ordan 10) John M. Starcher, Jr. 02) Waldemar A. Carlo, M.D.
05) Thomas A. McEachin 08) Michael A. Rucker 11) Shirley A. Weis 03) Paul G. Gabos 06) Roger J. Medel, M.D. 09) Guy P. Sansone 2. Proposal to approve the amendment and restatement of the Mednax, Inc. Amended and Restated 2008 Incentive Compensation
Plan. 3. Proposal to approve the amendment and restatement of the Mednax, Inc. 1996 Non-Qualified Employee Stock Purchase Plan, as amended. 4. Proposal to ratify the appointment of PricewaterhouseCoopers LLP
as our independent registered public accounting firm for the 2021 fiscal year. 5. Proposal to approve, by non-binding advisory vote, the compensation of our named executive officers for the 2020 fiscal year.
Board Recommends For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. D43204-P51249-Z79304
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jul 2023 to Jul 2024
